Funding for this research was provided by:
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham (n/a)
Birmingham VA Medical Center, Birmingham, Alabama, USA (n/a)
Text and Data Mining valid from 2019-02-28
Received: 27 September 2018
Accepted: 25 January 2019
First Online: 28 February 2019
Consent for publication
: Not applicable since there are no individually identifiable data.
: JAS has received research grants from Takeda and Savient pharmaceuticals and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, Medscape, Fidia pharmaceuticals and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies. Jas has previously served on the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and the ACR Quality of Care Committee; Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.